AnteNOR

Preventing breast cancer in Norway with polygenic risk-score tests

The AnteNOR project explores how to improve prevention and early detection of breast cancer in Norway. The project focuses on polygenic risk-score tests, a new type of technology that can provide a measure of someone’s personal risk to develop a disease.

It is possible to identify a person’s individual risk levels for common cancers with personalised screening, as many cancer risks arise from one’s genetic disposition. Breast cancer is a relevant cancer area, as the national screening programme starts to invite women for mammographies when they turn 50, although many women develop cancer before this age.

The project aims to create models for new screening programmes, where genetics-based screening can be included. It also investigates how these new approaches can be implemented in the clinic and national health service.

News articles

Project main progress

July – December 2021

AnteNOR project kick-off
Green ICT project was mentioned in Delfi Ärileht article
Mapped and interviewed Norwegian key stakeholders in the field of breast cancer and breast cancer mammography screening
Applied and received the ethical commitee approval for genetic analysis study
Analysis of Norwegian genetic data started
Antegenes became a member of Oslo Cancer Cluster
Presentation about Antegenes and AnteNOR project at Oslo Cancer Cluster virtual annual meeting on 15th of December

January – June 2022

Started cooperation with Oecona AS
Participated in EXPO 2020 Dubai for international scientific cooperations
Green ICT project was mentioned in e-Estonia blog article.
Development of the cost-benefit simulation study for Norwegian medical setting
AnteNOR seminar was organized in Oslo by Oslo Cancer Cluster and Antegenes
AnteNOR project clinical pilot study protocol created and ready
Application for conducting the AnteNOR clinical pilot is submitted to Regional Ethical Commitee

July – December 2022

Approval of the Ethics Committee to implement study in Oslo University Hospital and Vestre Viken Hospital was obtained.
Clinical study was registered in the ClinialTrials.gov database.
Clinical study logistics pathways were developed, study assistant was involved by Vestre Viken Hospital.
Retrospective performance assessment of Antegenes PRS in Norwegian data has been conducted. Initial results have been compiled and presented as a poster at the Nordic Society of Human Genetics and Precision Medicine 2022 conference “Precision Medicine Research And Implementation: Rebooting In The Nordics Post-Covid” (3-4 November 2022, Copenhagen, Denmark) (Akdeniz et al. “Implementation of polygenic risk score guided breast cancer prediction in Norwegian data”).
Oecona developed the cost-utility preliminary model for Norwegian medical setting. Collaboration with health economists of Sweden was launched.
Norway specific health technology assessment and implementation options specific to Norwegian healthcare were developed.
The article “Preventing breast cancer in Norway” was written and published on Oslo Cancer Cluster website.